ODX.L Regulatory News (ODX)

Omega Diagnostics Group PLC

("Omega" or the "Company")

Allersys® CE-Mark

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has CE-Marked an additional eight allergens to extend its menu to 49 allergens.

Omega's aim is to enhance the product offering on a continuous basis. The investment on developing the Allersys® product range is being supported by the research and development grant of up to £1.8 million, which the Company secured from Scottish Enterprise in August 2016. The Company's pipeline includes a further nine allergens which it aims to CE-Mark over the next few months.

Colin King, Chief Executive Officer of Omega, commented: "We are pleased to extend our Allersys® menu and we remain on track to add further allergen tests to the menu in line with our development timelines. As noted in our interim results announcement last week, we remain positive that we will conclude commercialisation discussions with Immunodiagnostic Systems in the near future."

Contacts: